ProKidney Bolsters Commercial Strategy with Greg Madison as CCO

ProKidney Corp. has appointed Greg Madison as Chief Commercial Officer to drive the company's commercial strategy for its potential cell therapy, rilparencel. Madison brings over two decades of executive leadership experience in biopharmaceutical companies and has a proven track record of building high-performing organizations and shaping commercial strategies. His appointment aims to position rilparencel for potential commercialization and address the unmet need for patients with advanced chronic kidney disease and diabetes.